Rx Pricing: Insulin Costs Would Go Up Under Senate Bill; Biden Pushes Summer Action On Broader Plan

CBO highlights the pharma-friendly nature of Senate’s plan to limit patient cost-sharing for insulin. Meanwhile, White House urges Senate to pass Democrat’s more comprehensive and pharma-negative drug pricing bill instead of waiting for the revival of the Build Back Better deal.

pills in shape of dollar sign
CBO says Senate insulin bill would raise the diabetes drug’s net price. • Source: Shutterstock

A Senate plan to tackle patient cost-sharing for insulin is estimated to increase the federal deficit by $23.3 bn over a decade, about double the impact of the insulin-provisions in a similar House bill.

The difference is largely due to pharma-friendly elements of the Senate bill that would among other things increase the average...

More from Pricing Debate

More from Market Access